Drug Discovery

Lyndra Therapeutics and Gilead Sciences to collaborate on development of ultra-long-acting HIV therapeutics

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies.

MorphoSys secures option to license Vivoryon’s QPCTL inhibitors for cancer

MorphoSys has signed an agreement with Vivoryon Therapeutics to obtain an exclusive option to license the latter’s small molecule glutaminyl-peptide cyclotransferase-like (QPCTL) inhibitors for developing oncology treatments.

PhoreMost, inStem enter structural biology alliance

PhoreMost, the UK-based biopharmaceutical company, has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India.

Boehringer Ingelheim, Yuhan sign £689m NASH license deal

Boehringer Ingelheim has signed a collaboration and license agreement with South Korean pharma company Yuhan, potentially worth up to $870m (£689m), for the latter’s fusion protein for the treatment of Nonalcoholic Steatohepatitis (NASH) and related liver diseases.

Rafael Pharmaceuticals, Ono Pharmaceutical to accelerate clinical development of cancer drug candidate CPI-613

Rafael Pharmaceuticals, a leader in the growing field of cancer metabolism-based therapeutics, has entered into an out-licensing agreement with Ono Pharmaceutical, a pharmaceutical company committed to creating innovative medicines.

AbbVie to buy Irish pharmaceutical firm Allergan for £49.4bn

US-based AbbVie has signed an agreement to acquire Irish pharmaceutical firm Allergan in a deal valued at around $63bn (£49.4bn).

Gilead, Carna Biosciences collaborate to develop novel immuno-oncology therapies

Gilead Sciences and Carna Biosciences announced that the companies have entered into a research and development collaboration to develop and commercialise small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform.

Alnylam announces progress with RNAi Therapeutics platform

Alnylam Pharmaceuticals has announced new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target.

Janssen announces collaboration with US universities to expand data science research in healthcare

Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced a collaboration with the University of California, Berkeley (UC Berkeley) and the University of California, San Francisco (UCSF), with the goal of inspiring data-driven approaches to improve health and develop the next generation of leaders in healthcare data sciences.